Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 vaccine programmes are expected to cost poorer countries an additional 56.6% on health budgets, compared with just 0.8% on wealthy countries’ health expenditure, according to new data from the United Nations Development Programme (UNDP), the World Health Organisation (WHO) and the University of Oxford.

Vaccine being administrered

According to the research, inequity will have a 'lasting and profound impact' on socio-economic recovery in low and lower-middle income countries unless there is urgent action to make vaccines affordable and accessible to everyone.

With the current cost of vaccines calculated at an average US$15.80, and without immediate global financial support, low-income countries are forecast to see health costs soar by more than half, to vaccinate fully a target of 70% of their populations. But high-income countries would have to increase spending by just 0.8 percent to achieve the same results. This would account for half of low-income countries' projected GDP growth in 2021, against 0.2% for high-income countries.

These insights come from the Global Dashboard on Vaccine Equity , a joint initiative from UNDP, WHO and Oxford’s Blavatnik School of Government, which combines the latest COVID-19 vaccination information with the most recent socio-economic data. It illustrates why vaccine equity is not only critical to saving lives but also to driving a fairer and faster recovery from the pandemic.

Read the full story on the University of Oxford website.

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.